These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study. Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472 [TBL] [Abstract][Full Text] [Related]
7. The 0.2-μg/day Fluocinolone Acetonide Intravitreal Implant in Chronic Noninfectious Posterior Uveitis: A 3-year Randomized Trial in India. Biswas J; Tyagi M; Agarwal M; Ophthalmol Sci; 2024; 4(1):100403. PubMed ID: 38027419 [TBL] [Abstract][Full Text] [Related]
9. Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye - evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN Bodaghi B; Nguyen QD; Jaffe G; Khoramnia R; Pavesio C J Ophthalmic Inflamm Infect; 2020 Nov; 10(1):32. PubMed ID: 33251553 [TBL] [Abstract][Full Text] [Related]
10. Intravitreal Fluocinolone 0.19mg Implant in the Management of Chronic Non-Infectious Uveitis: 12-Month Outcomes from a Single Tertiary Centre. Pockar S; Leal I; Chhabra R; Jones NP; Steeples LR Ocul Immunol Inflamm; 2023 Oct; 31(8):1572-1578. PubMed ID: 34124978 [TBL] [Abstract][Full Text] [Related]
11. Rapid Structural and Functional Improvements with the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Patients with DME and Low Visual Acuity: 6-Month Data from the UAE. Elbarky AM Clin Ophthalmol; 2020; 14():823-830. PubMed ID: 32214793 [TBL] [Abstract][Full Text] [Related]
12. Real-World Experience of Fluocinolone Acetonide 0.19 mg in the Management of Non-Infectious Uveitis. Logeswaran A; Azzopardi M; Demir B; D'Alonzo G; Chong YJ; Addison P; Pavesio C Ocul Immunol Inflamm; 2024 Jul; ():1-6. PubMed ID: 39042811 [TBL] [Abstract][Full Text] [Related]
13. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema. Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913 [TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Jaffe GJ; McCallum RM; Branchaud B; Skalak C; Butuner Z; Ashton P Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of 0.19-mg Fluocinolone Acetonide Implant in Postoperative Cystoid Macular Edema after Pars Plana Vitrectomy: the ILUCYD study. Motloch K; Soler V; Delyfer MN; Vasseur V; Wolff B; Issa M; Dot C; Massé H; Weber M; Comet A; Hitzl W; Matonti F; Creuzot-Garcher C; Tadayoni R; Kodjikian L; Couturier A Ophthalmol Retina; 2024 Jul; ():. PubMed ID: 39004282 [TBL] [Abstract][Full Text] [Related]
16. Fluocinolone Acetonide Implant for Uveitis: Dissecting Responder and Non-Responder Outcomes at a Tertiary Center. Abu Arif J; Knecht VA; Rübsam A; Lussac V; Jami Z; Pohlmann D; Müller B; Pleyer U Biomedicines; 2024 May; 12(5):. PubMed ID: 38791073 [TBL] [Abstract][Full Text] [Related]
17. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials. Holden SE; Kapik B; Beiderbeck AB; Currie CJ Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759 [No Abstract] [Full Text] [Related]